Board of Directors
A Board of Directors with 150 years of experience in business,
entrepreneurship, scientific & clinical research, and disease management.
Prof. Christian Bréchot
Co-founder & Chairman of the Board
Prof. C. Bréchot is internationally renowned as the former head of French institutes (Pasteur institute, Inserm and Mérieux Institute). He is hepatologist, professor at the university of South Florida, and Chairman of the Global Virus Network.
Dr. Gilles Amouyal
Co-founder & Vice-President
Dr. Gilles Amouyal is an expert in hepato-gastro-enterology and former head of clinics. He is CSO of a biotech company and a Board Member of several biotech companies.
Dr. Paul Amouyal
Co-founder & Vice-President
Dr. Paul Amouyal is an expert in hepato-gastro-enterology and former head of clinics. He is CEO of a biotech company and a board member of several biotech companies.
Dr. Christophe Magnan
Head of Research/ Co-Founder
Prof. Christophe Magnan is professor at the University of Paris. He is an expert in glucose homeostasis and signed more than 150 scientific papers. He is head of REGLYS within UMR 8251, with which THAC collaborates to complete the preclinical studies.
A few things we’re great at
The Company is governed by a Board of Directors, chaired by Prof. Christian Bréchot who is also Chief Executive Officer (CEO) of THAC’s US affiliate.
The Board of Directors determines the Company’s strategy and oversees its implementation.
The Board of Directors is composed of some cofounders of the company: Pr. Christian Bréchot, Dr. Paul Amouyal, Dr. Gilles Amouyal, and Dr. Christophe Magnan.
Owned by Co-Founders and Ready for clinical study!
THAC, The Healthy Aging Company, is a privately owned biopharmaceutical company based in France and the US that aims to develop a range of first-in-class drug candidates targeting T2DM and its complications.
♦ Its pipeline could lead to potential game-changers in patient care and disease management. THAC primarily focuses on Type 2 diabetes mellitus, a condition with still unmet medical needs.
♦ THAC envisions that by fighting insulin resistance, the root cause of T2DM, major breakthroughs could be achieved in treating T2DM and preventing severe related complications such as peripheral neuropathy (e.g., diabetic foot wounds, amputations).
♦ THAC drug candidates have a unique and innovative mechanism of action that targets oxidation and inflammation.
♦ THAC drug candidates are intended to delay disease progression, improve patient’s quality of life, delay premature death, and prevent T2DM complications; peripheral neuropathy is a severe complication for which there is no treatment available, e.g., diabetic foot wounds and amputations.
